Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference


Summit Therapeutics plc

(‘Summit' or the ‘Company')

Summit Therapeutics to Present at H. C. Wainwright & Co.Global Life Sciences Conference

Oxford, UK, and Cambridge, MA, US, 2 April 2019 - Summit Therapeutics plc (NASDAQ: SMMT, AIM:SUMM), a leader in new mechanism antibiotic innovation, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the H. C. Wainwright & Co.Global Life Sciences Conference on 8 April 2019 at 4:10pm BST in London.

A live webcast of the presentation will be available in the Investors section of the Company's website, A replay of the webcast will be available from the same location soon after the live presentation.

About Summit Therapeutics

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit and follow us on Twitter @summitplc.


Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson
MSL Group (US) Tel: +1 781 684 6557
Jon Siegal
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson /
Lindsey Neville


Source: Summit Therapeutics plc

In This Story